Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        101-110 of 217 results for 'impetigo'

        Refine search

        Research

        Getting to grips with invasive group A streptococcal infection surveillance in Australia: are we experiencing an epidemic?

        Asha Rosemary Bowen Wyber AC R BA MBBS DCH FRACP PhD GAICD OAM MBChB MPH FRACGP PhD Head, Healthy Skin and ARF Prevention Senior Research Fellow Head ...

        Research

        Burden of skin disease in two remote primary healthcare centres in northern and central Australia

        Skin infections are an under-appreciated and dominant reason for presentation to primary healthcare centres in these indigenous communities ...

        Research

        Evaluation of Pediatric HIV Postexposure Prophylaxis Guideline Following Child Sexual Assault in Western Australia

        HIV postexposure prophylaxis (PEP) following child sexual assault (CSA) is recommended in select cases. High rates of poor adherence to PEP are reported. We evaluated adherence to the recommended management of children following CSA at the tertiary pediatric facility in Western Australia and compared our approach with international guidelines. ...

        Research

        The inequitable burden of group A streptococcal diseases in Indigenous Australians

        Given the ongoing mortality and morbidity from GAS infections, we must address more effectively the treatment and prevention of GAS impetigo and pharyngitis ...

        Research

        Modes of transmission and attack rates of group A Streptococcal infection: a protocol for a systematic review and meta-analysis

        Group A Streptococcus (Strep A) is an important cause of mortality and morbidity globally. This bacterium is responsible for a range of different infections and post-infectious sequelae. Summarising the current knowledge of Strep A transmission to humans will address gaps in the evidence and inform prevention and control strategies. The objective of this study is to evaluate the modes of transmission and attack rates of group A streptococcal infection in human populations. ...

        Research

        Roadmap to incorporating group A Streptococcus molecular point-of-care testing for remote Australia: a key activity to eliminate rheumatic heart disease

        Jonathan Asha Dylan Rosemary Janessa Carapetis AM Bowen Barth Wyber Pickering JR AC DB R Dr AM MBBS FRACP FAFPHM PhD FAHMS BA MBBS DCH FRACP PhD ...

        Research

        Overlapping Streptococcus pyogenes and Streptococcus dysgalactiae subspecies equisimilis household transmission and mobile genetic element exchange

        Streptococcus dysgalactiae subspecies equisimilis and Streptococcus pyogenes share skin and throat niches with extensive genomic homology and horizontal gene transfer possibly underlying shared disease phenotypes. ...

        Research

        Clinical experience with SUBA-itraconazole at a tertiary paediatric hospital

        Itraconazole remains a first-line antifungal agent for certain fungal infections in children, including allergic bronchopulmonary aspergillosis (ABPA) and sporotrichosis, but poor attainment of therapeutic drug levels is frequently observed with available oral formulations. A formulation of 'SUper BioAvailability itraconazole' (SUBA-itraconazole; Lozanoc®) has been developed, with adult studies demonstrating rapid and reliable attainment of therapeutic levels, yet paediatric data are lacking. ...

        Research

        Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines

        Systematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations ...

        Research

        A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart disease

        Few children and adolescents receiving BPG as secondary prophylaxis will achieve concentrations >0.02 mg/L for the majority of the time between injections ...

        Page 11 of 22